2.1
Selpercatinib (Retsevmo, Eli Lilly) as monotherapy is indicated for 'the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor'.
2 Information about selpercatinib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for selpercatinib.
Price
2.3
The list price for selpercatinib is £2,184 per pack of 56 x 40 mg capsules; £6,552 per pack of 168 x 40 mg capsules; £4,368 per pack of 56 x 80 mg capsules and £8,736 per pack of 112 x 80 mg capsules (excluding VAT; BNF online, accessed September 2024).
2.4
The company has a commercial arrangement. This makes selpercatinib available to the NHS with a discount. The size of the discount is commercial in confidence.